| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8992958 | Annales Pharmaceutiques Françaises | 2005 | 7 Pages |
Abstract
Our experience and, therefore, our own tools allow us to design new inhibitors of growth factor receptor tyrosine kinase, PDK-1 and farnesyltransferase activities. These original compounds could selectively switch off one or several steps of the multifunctional pathway and constitute lead compounds in the design of new classes of potent drugs.
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
N. Pommery, J.-P. Hénichart,